<DOC>
	<DOCNO>NCT02752776</DOCNO>
	<brief_summary>Study effect secukinumab 300 mg s.c. quality life ( QoL ) psoriasis patient without prior exposure systemic therapy .</brief_summary>
	<brief_title>A Study Evaluate Clear Skin Effect Quality Life Patients With Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman age least 18 year time Screening . Moderate severe plaquetype psoriasis diagnose least 3 month prior Screening candidate systemic therapy . Other protocol define inclusion criterion may apply . Please refer protocol . Forms psoriasis moderate severe plaquetype psoriasis , e.g . druginduced psoriasis Screening . Patients previous treatment agent target interleukin ( IL ) 17 directly IL17 receptor A ( e.g . secukinumab , ixekizumab , brodalumab ) . Pregnant nursing ( lactate ) woman Women childbearing potential unless use effective contraception Other protocoldefined exclusion criterion may apply . Please refer protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Moderate severe plaque psoriasis</keyword>
</DOC>